Main menu


iNtRON has developed a novel CRISPR/Cas technology dedicated to bacteriophages as the PHAGERUS® platform

  • CRISPR/Cas system for not bacteria Escherichia coli Also Streptococcus pyogenes

  • Customized gene-editing technology for your own engineered bacteriophage

  • Validating the efficacy of SARS-CoV-2 mimotope-loaded PHAGERUS® platform

boston When Seoul, South Korea, August 9, 2022 /PRNewswire/ — iNtRON Biotechnology (“iNtRON”, today announced that iNtRON has developed a proprietary CRISPR/Cas system customized for the genetic modification of specific bacteria and corresponding bacteriophages Did.

Officials at iNtRON said the technology would allow the company to freely edit different genes in the bacteriophage gene to have new or desired functions.

IntRON’s PHAGERUS® The platform technology is being developed on the hypothesis that bacteriophages go beyond the common notion of ‘bacteria-killing viruses’ and play an important role in maintaining the human immune system. In other words, vast numbers of bacteriophages have outlived humans, and some are involved in controlling certain harmful viruses and influencing the human immune system.

Here iNtRON has been working on PHAGERUS using bacteriophages known to be safe for humans as a preventive and therapeutic agent for viral diseases.® A platform technology that facilitates the manipulation of multiple structural genes that play morphological and functional roles in bacteriophages. Description of PHAGERUS® The platform technology, the original technology for bacteriophage-specific gene editing and virus control, maintains the original functions of the bacteriophage (bacteriophage infectivity and bacterial control) while adding properties that enable effective control of specific viruses. I’m focusing on that.

“The virus that targets PHAGERUS is® The platform was developed based on the “ViP Cycle Hypothesis (Bacteria-Virus-Phage Relationship)” to screen natural bacteriophage candidates for vaccines and utilizes a proprietary modified phage display technology to utilize antigenic peptides (Ag -peptides; mimotopes) to secure candidates. “

In this regard, we plan to continue developing antiviral cocktail agents that combine natural bacteriophages that exist in nature. We aim to utilize mimotopes as genetic engineering technology. Mimotopes could ultimately be applied to engineered bacteriophage agents.

Company name Mockup-PHAGERUS® Bringing together the bacteriophage and its platform technology, we label specific bacteriophage outer-membrane protein regions using gene-editing technology customized to mimotope bacteriophages that can exert antiviral effects. Mockup – PHAGERUS® The major difference from the conventional technology is that general hosts (Escherichia coli, Streptococcus pyogenes).

In addition, we developed specific bacterial vectors using the CRISPR/Cas system derived from the host of choice, allowing insertion, removal and replacement of specific genes in candidate bacteriophages and used as Mockup-PHAGERUS.®then inserted into specific hosts and selectively activated against specific bacteria and their corresponding bacteriophages

Yun, Kyung WoniNtRON CEO said:® The platform technology is of value for its unprecedented gene-editing capabilities in bacterial strains. In the future, we plan to present Mockup-PHAGERUS with various mimotopes expected to be active against SARS-CoV-2 and use them to validate vaccine candidates.®Yun continued, “CRISPR/Cas-based gene-editing technology will be used as a platform technology to freely modify a variety of beneficial bacteriophages and expand into different antiviral areas (influenza virus and G4 virus). We hope that this will be the development of drugs.”

About PHAGERUS® platform

IntRON’s PHAGERUS® The technology has discovered the applicability of bacteriophages as virus-neutralizing vaccines and therapeutics, securing a number of related core technologies, PHAGERUS.® Humoral and cell-mediated immunity can be induced by oral or nasal vaccines based on natural bacteriophages with virus-targeting homology or engineered bacteriophages that express antigens or virus-like particles on their surface. increase.

About iNtRON Biotechnology, Inc.

iNtRON is a leader in bacteriophage-based technology for the development and exploration of the “Immunology and Immunotherapy” market. Pursuing global research and business development (R&BD) investments since its inception, and accelerating development after entering the IPO on KOSDAQ, the company has developed various “first concept” biopharmaceuticals and conducted clinical studies. By doing so, we have refined the innovation of new biopharmaceuticals. step by step. We are committed to developing groundbreaking innovations in infectious diseases and in the field of Immunity and Immunotherapy.

About iNtODEWorld Co., Ltd.

iNtRON establishes iNtO, a wholly owned subsidiary in the United StatesDE2017 World Co., Ltd.DEWORLD was first registered Delaware Headquarters is currently bostonintoDEWORLD provides iNtRON news, updates and platform development progress to potential global partners and collaborators, as well as original US R&BD productions.


Yoon, Kyung Won (Kevin) / CEO, Vice President /
shins, Daegu (TK) / BD Team Leader /
BD Team /

iNtRON Biotechnology Co., Ltd.

148 708, Sagimakgol-ro, Jungwon-gu, Seongnam-si
Gyeonggi-do, Republic of Korea

into theDEWorld Co., Ltd.
1500 District Avenue, Suite 2097, Burlington, Massachusetts 01803, united states of america

That’s the intron.


View original content:

Source: iNtRON Biotechnology, Inc.